Traditional Chinese medicine composition for treating radiation bowel disease as well as preparation method and application of traditional Chinese medicine composition
By using traditional Chinese medicine compositions composed of Pueraria root, Scutellaria baicalensis, Coptis chinensis and roasted licorice, the prior art problems of radiation enteropathy treatment are solved, the intestinal function and antioxidant capacity are significantly improved, and a safe and efficient treatment plan is provided.
Patent Information
- Application Number
- CN202410876798.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-02
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art cannot effectively treat radiation enteropathy, and common drugs have side effects, high prices and high toxicity, and lack ideal treatment measures.
Provide a traditional Chinese medicine composition, made of Pueraria root, Scutellaria baicalensis, Coptis chinensis and roasted licorice, is used to maintain intestinal barrier function, reduce intestinal obstruction and intestinal bleeding, promote the proliferation of intestinal mucosal epithelial cells, improve intestinal blood vessel permeability, and Improve the antioxidant ability of intestinal tissue cells.
It significantly improved the therapeutic effect of radiation enteropathy, reduced intestinal epithelial cell damage and fibrotic lesions, improved the antioxidant ability of intestinal tissues, and reduced damage to the intestinal mucosa after radiation.
Smart Images

Figure BDA0004923305910000041 
Figure BDA0004923305910000051 
Figure BDA0004923305910000052
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of traditional Chinese medicines, and in particular relates to a traditional Chinese medicine composition for treating radiation enteropathy, and a preparation method and application thereof. Background Art
[0002] Radiation-induced intestinal injury (RII) refers to intestinal complications caused by radiotherapy for pelvic, abdominal or retroperitoneal tumors, which can affect the small intestine, colon and rectum. Although advances in radiotherapy technology have greatly reduced the damage of radiotherapy to tissues outside the target area, 90% of patients receiving radiotherapy will experience acute symptoms such as diarrhea, abdominal pain, and blood in the stool. So far, clinical treatment of RII mostly uses radioprotectants such as cytokines, hormone drugs and thiol compounds, but their application is limited by many side effects, high prices and high toxicity. Therefore, the development of effective drugs for RII is very necessary.
[0003] The pathogenesis of RII involves factors such as intestinal epithelial cell damage, intestinal inflammatory response, oxidative stress activation and changes in intestinal flora. The pathological mechanism is complex and the process is diverse. There is currently no ideal treatment measure.
[0004] In view of the problem that there are few drugs for treating radiation enteropathy at present, the present application proposes a Chinese medicine composition for treating radiation enteropathy, and a preparation method and use thereof. There is no literature report on the use of this Chinese medicine composition for treating radiation enteropathy. Summary of the invention
[0005] In order to solve the above problems, the present invention provides a Chinese medicine composition for treating radiation enteropathy and its preparation method and application. The Chinese medicine composition of the present invention has a very good therapeutic effect on radiation enteropathy.
[0006] Therefore, the first object of the present invention is to provide a traditional Chinese medicine composition for treating radiation enteropathy, which is made of the following traditional Chinese medicine raw materials in parts by weight: 120-200 parts of Pueraria root, 20-100 parts of Scutellaria baicalensis, 20-100 parts of Coptis chinensis and 10-80 parts of Radix Glycyrrhizae Preparata.
[0007] Preferably, the Chinese medicine composition for treating radiation enteropathy is made of the following Chinese medicine raw materials in parts by weight: 140-180 parts of Pueraria root, 40-80 parts of Scutellaria baicalensis, 40-80 parts of Coptis chinensis and 30-60 parts of Radix Glycyrrhizae Preparata.
[0008] Further preferably, the Chinese medicine composition for treating radiation enteropathy is made of the following Chinese medicine raw materials in parts by weight: 168 parts of Pueraria root, 63 parts of Scutellaria baicalensis, 63 parts of Coptis chinensis, and 42 parts of Radix Glycyrrhizae Preparata.
[0009] The second object of the present invention is to provide the use of the above-mentioned Chinese medicine composition in the preparation of medicines for treating radiation enteropathy.
[0010] Preferably, the radiation enteropathy is selected from the group consisting of acute / chronic enteropathy, intestinal fibrosis and enteritis caused by x-rays, gamma-rays, alpha-rays, beta-rays or neutron rays.
[0011] In a specific embodiment, the drug can be used to maintain intestinal barrier function, alleviate intestinal obstruction, and improve intestinal hypomotility.
[0012] In a specific embodiment, the drug can be used to promote the proliferation of intestinal mucosal epithelial cells, improve intestinal vascular permeability, and alleviate symptoms such as ulcers and intestinal bleeding.
[0013] In a specific embodiment, the drug can be used to reduce fibrotic lesions after the repair of intestinal epithelial cell damage (apoptosis and DNA damage).
[0014] In a specific embodiment, the Chinese medicine composition can be used to improve the antioxidant capacity of intestinal tissue cells and improve the aging and apoptosis of intestinal tissue cells.
[0015] The third object of the present invention is to provide a medicine for treating radiation enteropathy, which comprises the above-mentioned Chinese medicine composition and pharmaceutically acceptable excipients.
[0016] Preferably, the drug is administered orally or by enema, preferably orally.
[0017] Preferably, the medicine is a decoction, powder, pill, granule, tablet, capsule, syrup or mixture, more preferably a capsule, granule or tablet.
[0018] The fourth object of the present invention is to provide a method for preparing the drug for treating radiation enteropathy, which comprises the following steps: decocting four Chinese medicinal materials with water, filtering, combining the filtrate and concentrating it into an extract.
[0019] Preferably, the amount of water added to the decoction of the Chinese medicinal material is 6 to 10 times of its mass; the decoction time is 1 to 3 hours each time, and the decoction is performed 2 to 3 times; the concentration temperature is 60° C.; the relative density of the concentrated extract is 1.10 to 1.20 (50 to 60° C.);
[0020] More preferably, the amount of water added to the decoction of the Chinese medicinal material is 8 times its mass, the decoction time is 2 hours, the decoction is performed twice, and the relative density of the concentrated extract is 1.10 (50-60° C.).
[0021] Preferably, the method for preparing the drug for treating radiation enteropathy further comprises the following steps:
[0022] Adding dextrin and lactose to the extract, wherein the mass ratio of the extract to dextrin and lactose is 1-3:1-6:0.5-2, making wet granules, drying and sieving the whole granules to obtain granules; or
[0023] The extract is dried, crushed, mixed to obtain dry extract powder, and directly filled into capsules to obtain capsules; or
[0024] The extract is dried, crushed, and mixed to obtain dry paste powder, dextrin is added, and 90% ethanol is used as a binder to prepare wet granules, which are granulated after drying, and magnesium stearate and / or low-substituted hydroxypropyl cellulose (L-HPC) and / or polyethylene glycol and / or sodium carboxymethyl starch are added, and then tableting is performed to obtain tablets; wherein the mass ratio of the dry paste powder to dextrin, magnesium stearate or polyethylene glycol, low-substituted hydroxypropyl cellulose (L-HPC) or sodium carboxymethyl starch is 3-5:3-5:0.1-0.3:0.5-1.
[0025] The Chinese medicine composition for treating radiation enteropathy of the present invention can treat acute / chronic enteropathy, intestinal fibrosis and enteritis caused by x-rays, gamma rays, alpha rays, beta rays and neutron rays, etc. Pharmacodynamic tests show that the Chinese medicine composition of the present invention can protect the integrity of the intestinal mucosal barrier, improve intestinal vascular permeability and aging and pathological changes of intestinal tissue cells, and reduce fibrotic lesions after intestinal epithelial cell damage and repair, and has a significant therapeutic effect on radiation enteropathy. DETAILED DESCRIPTION
[0026] Typical embodiments are listed below to further illustrate the present invention, but do not constitute limitations on the protection scope of the present invention.
[0027] Preparation Example 1
[0028] Four Chinese medicinal raw materials, namely, 130g of Pueraria root, 20g of Scutellaria baicalensis, 35g of Coptis chinensis, and 14g of Radix Glycyrrhizae, were added with 8 times the amount of water and decocted twice, each time for 2 hours. The filtrates were combined and concentrated at 60°C to an extract with a relative density of 1.10. Dextrin and lactose were added to the extract, wherein the mass ratio of the extract to dextrin and lactose was 1:1:1, and wet granules were made. After drying, the whole granules were sieved to obtain granules.
[0029] Preparation Example 2
[0030] The granules were prepared in the same manner as in Example 1, except that the Chinese medicinal raw materials were 195 g of Pueraria root, 94 g of Scutellaria baicalensis, 87 g of Coptis chinensis, and 76 g of Radix Glycyrrhizae Preparata, and the mass ratio of the extract to dextrin and lactose was 1:2:1.
[0031] Preparation Example 3
[0032] Granules were prepared in the same manner as in Example 1, except that the Chinese medicinal raw materials were 168 g of Pueraria root, 63 g of Scutellaria baicalensis, 63 g of Coptis chinensis, and 42 g of Radix Glycyrrhizae Preparata, and the mass ratio of the extract to dextrin and lactose was 1:1.5:0.5.
[0033] Preparation Example 4
[0034] Four Chinese medicinal raw materials, namely, 172g of Pueraria root, 59g of Scutellaria baicalensis, 93g of Coptis chinensis, and 78g of Radix Glycyrrhizae, were added with 8 times the amount of water and decocted twice, each time for 2 hours. The filtrates were combined and concentrated at 60°C to an extract with a relative density of 1.10. The extract was dried, crushed, mixed to obtain a dry paste powder, and directly filled into capsules to obtain capsules.
[0035] Preparation Example 5
[0036] The capsules were prepared in the same manner as in Example 4, except that the Chinese medicinal raw materials were 189 g of Pueraria root, 87 g of Scutellaria baicalensis, 54 g of Coptis chinensis, and 47 g of Radix Glycyrrhizae Preparata.
[0037] Preparation Example 6
[0038] Four Chinese medicinal materials, namely, 123 g of Pueraria root, 25 g of Scutellaria baicalensis, 74 g of Coptis chinensis, and 53 g of Radix Glycyrrhizae Preparata, are added with 8 times the weight of water and decocted twice, each time for 2 hours, filtered, and the filtrates are combined and concentrated at 60°C to form an extract with a relative density of 1.10. The extract is dried, crushed, and mixed to obtain a dry paste powder, dextrin is added, and wet granules are prepared with 90% ethanol as a binder. After drying, the granules are sized, magnesium stearate and low-substituted hydroxypropyl cellulose (L-HPC) are added, and then tabletted to obtain tablets; wherein the mass ratio of the dry paste powder to dextrin, magnesium stearate, and low-substituted hydroxypropyl cellulose (L-HPC) is 5:4:0.1:0.4.
[0039] Preparation Example 7
[0040] Tablets were prepared by the same method as in Example 6, except that the Chinese medicinal raw materials were 138 g of Pueraria lobata, 46 g of Scutellaria baicalensis, 59 g of Coptis chinensis, and 36 g of Radix Glycyrrhizae Preparata, and the mass ratio of dry paste powder to dextrin, magnesium stearate, and low-substituted hydroxypropyl cellulose (L-HPC) was 4:3:0.2:1.
[0041] Preparation Example 8
[0042] Tablets were prepared by the same method as in Example 6, except that the Chinese medicinal raw materials were 156 g of Pueraria lobata, 55 g of Scutellaria baicalensis, 62 g of Coptis chinensis, and 39 g of Radix Glycyrrhizae Preparata, and the mass ratio of dry paste powder to dextrin, polyethylene glycol, and low-substituted hydroxypropyl cellulose (L-HPC) was 3:5:0.3:0.5.
[0043] Preparation Example 9
[0044] Tablets were prepared by the same method as in Example 6, except that the Chinese medicinal raw materials were 178 g of Pueraria lobata, 32 g of Scutellaria baicalensis, 79 g of Coptis chinensis, and 21 g of Radix Glycyrrhizae Preparata, and the mass ratio of dry paste powder to dextrin, magnesium stearate, and sodium carboxymethyl starch was 4:4:0.1:1.
[0045] The following test examples are used to further illustrate the extraction and preparation process of the Chinese medicine composition of the present invention and its therapeutic effect on radiation enteropathy.
[0046] Test Example 1: Study on extraction process
[0047] (1) Selection of the amount of water added: In order to explore the process conditions of water extraction of the Chinese medicine composition, the amount of solvent water added during extraction was investigated with the extract yield as an indicator. Weigh three portions of four medicinal materials, add 6, 8 and 10 times the amount of water, decoct twice, each time for 2 hours, filter, combine the filtrates and concentrate them into an extract with a relative density of 1.10 (50-60°C), and calculate the extract yield (see Table 1).
[0048] Table 1 Results of water addition
[0049]
[0050] The test results show that when the extract yield is used as the evaluation index, the extract yield is the lowest when 6 times the amount of water is added; when 8 or 10 times the amount of water is added, the extract yield is not much different. From the perspective of energy saving, it is more appropriate to choose to add 8 times the amount of water.
[0051] (2) Selection of decoction times: In order to explore the process conditions of water extraction of the Chinese medicine composition, the extract yield was used as an indicator to investigate the decoction times during extraction. Weigh three portions of four medicinal materials, add 8 times the amount of water, decoct 1 to 3 times, each time for 2 hours, filter, combine the filtrates and concentrate them into an extract with a relative density of 1.10 (50-60°C), and calculate the extract yield (see Table 2).
[0052] Table 2 Results of investigation on decoction times
[0053]
[0054] The test results show that, taking the extract yield as the evaluation index, the extract yield when extracted twice is not much different from that when extracted three times, which means that the extract has been basically extracted after two decoctions. Considering energy saving and time saving, it is more appropriate to choose to decoct twice.
[0055] (3) Selection of decoction time: In order to explore the process conditions of water extraction of the Chinese medicine composition, the decoction time during extraction was investigated with the extract yield as an indicator. Weigh three portions of four medicinal materials, add 8 times the amount of water, decoct twice, each time for 1 to 3 hours, filter, combine the filtrates and concentrate them into an extract with a relative density of 1.10 (50 to 60°C), and calculate the extract yield (see Table 3).
[0056] Table 3 Decoction time investigation results
[0057]
[0058] The test results show that, taking the extract yield as the evaluation indicator, there is little difference between extracting for 2 hours each time and extracting for 3 hours each time. Considering energy saving and time saving, it is more appropriate to choose to decoct for 2 hours.
[0059] Test Example 2: Study on Forming Process
[0060] The extract after filtration and concentration is very viscous and difficult to preserve. It needs to be prepared into a preparation by adding appropriate amount of auxiliary materials, taking the preparation of granules as an example.
[0061] Choice of granulation method: The granules made by wet method have the advantages of high preparation uniformity, good fluidity and strong wear resistance after surface wetting. They are most widely used in the pharmaceutical industry, so wet granulation is suitable.
[0062] Sample preparation: Weigh a dose of medicine and operate according to the preferred process.
[0063] Screening of auxiliary materials: dextrin, soluble starch, corn starch were added separately, and lactose was used as a flavoring agent (see Table 4).
[0064] Table 4 Screening of excipients
[0065]
[0066]
[0067] The test results show that when the granules are granulated with the ratio of extract: dextrin: lactose = 1:1.5:0.5, the granules have better uniformity, solubility and taste.
[0068] Experimental Example 3: Chinese herbal medicine composition reduces damage to intestinal mucosal barrier after irradiation
[0069] In this experiment, healthy adult male C57BL / 6J mice aged 6 to 8 weeks (20 to 22 g) were used, and subsequent experiments were conducted after 1 week of adaptive feeding. The experimental process and related operations were approved by the Experimental Animal Center of the Fourth Military Medical University.
[0070] Experimental grouping and dosing: The mice were divided into a normal group, a model group, and dosing groups including: Preparation Example 1 group, Preparation Example 2 group, Preparation Example 3 group, Preparation Example 4 group, Preparation Example 5 group, Preparation Example 6 group, Preparation Example 7 group, Preparation Example 8 group, and Preparation Example 9 group, and the dosage was 3 g / kg.
[0071] Implementation method: The mouse radiation intestinal injury model was established by whole-body irradiation of mice at a dose rate of 400MU / min and a 6MV X-ray mode with a source-skin distance of 100cm. The mice were sacrificed after continuous oral administration for 7 days after modeling. Hematoxylin-eosin (H&E) staining of mouse intestinal tissue and Chiu's score of intestinal mucosa. The intestinal tissue of mice was fixed in 4% paraformaldehyde for 24 hours and then embedded in paraffin and sliced. The tissue sections were soaked in xylene I and II for 30 minutes respectively; then soaked in different concentrations of ethanol in turn, rinsed with distilled water for 3 minutes; then H&E staining was performed; neutral resin was used to seal the sections, and the sections were observed and photographed under an optical microscope. The pathological changes of intestinal mucosa were scored using the Chiu's score. The grades are as follows: 0 points, normal; 1 point, widening of the subepithelial space at the top of the villi; 2 points, further expansion of the subepithelial space at the top of the villi, elevation of the epithelium at the tip of the villi and separation of the lamina propria; 3 points, the villous epithelium falls off in pieces; 4 points, the epithelium falls off completely, leaving only the lamina propria; 5 points, the lamina propria layer collapses, with bleeding and ulcers.
[0072] Statistical analysis: Experimental data were expressed as mean ± standard deviation. The comparison among the groups was analyzed by t-test, and P<0.05 indicated significant difference.
[0073] Experimental results: The intestinal villi of the mice in the model group were severely broken and the number of crypts was greatly reduced; the groups of Preparation Examples 1-9 effectively reduced the intestinal tissue damage caused by X-rays, and the Chiu's score results of intestinal tissue damage (Table 5-1) showed that the drug group of Preparation Example 3 had the best effect.
[0074] Table 5-1 Evaluation of Chinese medicine combination on RII intestinal mucosal pathological damage
[0075]
[0076] ##P<0.01 compared with the normal group; **P<0.01 compared with the model group
[0077] The following test examples were given using the drug prepared in Preparation Example 3.
[0078] Experimental grouping and dosing: The mice were divided into a normal group, a model group, a high-dose 3 g / kg Chinese medicine composition group, a medium-dose 1.5 g / kg Chinese medicine composition group, and a low-dose 0.75 g / kg Chinese medicine composition group.
[0079] Experimental method: Same as above
[0080] Experimental results: In the model group, the intestinal villi collapsed and shortened, the intestinal villus epithelial cells fell off, and the number of crypts decreased, while the Chinese medicine composition could protect the intestinal villi and crypts in a dose-dependent manner, reduce the damage to intestinal epithelial cells, and maintain the physiological state of the intestine. The results of H&E staining showed that the Chinese medicine composition of Preparation Example 3 could significantly reduce the atrophy of the intestinal mucosa and the shedding of intestinal villi in mice after RII, reduce the inflammatory infiltration of intestinal epithelial cells, maintain the number of intestinal crypts, and reduce the Chiu's score of intestinal tissue damage (Table 5-2), indicating that the Chinese medicine composition can reduce the damage to the intestinal mucosal barrier after irradiation.
[0081] Table 5-2 Evaluation of Chinese herbal medicine combination on RII intestinal mucosal pathological damage
[0082]
[0083] ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group
[0084] Experimental Example 4: Chinese herbal medicine composition promotes proliferation of intestinal tissue cells in mice after radiation damage
[0085] Implementation method: Immunohistochemical staining of mouse intestinal tissue. Using the Ki67 protein immunohistochemical kit, Ki67 protein immunohistochemical staining in intestinal tissue was performed according to the instructions; tissue sections were dewaxed, antigen repaired, 0.3% TritonX-100 permeabilized, endogenous peroxidase blocked, blocked and incubated with primary antibody, secondary antibody, SABC, color development and counterstaining, dehydrated, transparent and sealed, and the sections were observed under a microscope.
[0086] Statistical analysis: Experimental data were expressed as mean ± standard deviation. The comparison among the groups was analyzed by t-test, and P<0.05 indicated significant difference.
[0087] Experimental results: Ki67 is a nuclear protein that is closely related to the activity of cell proliferation and can be used as a marker for cell proliferation. Compared with the normal control group, the expression of Ki67 protein in the intestine of mice after radiation was significantly reduced (P<0.01). Compared with the model group, the positive expression of Ki67 in the intestinal tissue of mice in the Chinese medicine composition administration group was significantly increased (P<0.01), indicating that the proliferation ability of cells was enhanced. It shows that the Chinese medicine composition can promote the proliferation of intestinal tissue cells of mice after radiation damage (Table 6).
[0088] Experimental Example 5: Chinese herbal medicine composition inhibits radiation-induced apoptosis of intestinal tissue cells in mice
[0089] Implementation method: TUNEL kit detection. According to the instructions, the tissue sections were placed in a 70°C oven for 1 hour for dewaxing, and then washed in xylene, anhydrous ethanol, and various concentration gradient ethanol in sequence, and then rinsed twice in tissue permeabilization solution; the reaction solution was prepared according to the instructions; the reaction solution was added dropwise to the tissue sections, and then the sections were placed in a wet box and placed in a 37°C oven for 1 hour for reaction; the cell nuclei were counterstained according to the instructions; after the reaction, the sections were sealed with a sealing agent containing anti-fluorescence quenching, and then image acquisition and analysis were performed.
[0090] Statistical analysis: Experimental data were expressed as mean ± standard deviation. The comparison among the groups was analyzed by t-test, and P<0.05 indicated significant difference.
[0091] Experimental results: Compared with the normal control group, the number of apoptotic cells in the intestinal tissue of mice after radiation increased significantly (P<0.01), and the intestinal tissue was severely damaged. Compared with the radiation model group, the number of apoptotic cells in the Chinese medicine composition group decreased significantly (P<0.01), and it was dose-dependent, indicating that the Chinese medicine composition can effectively inhibit the apoptosis of intestinal tissue cells in mice caused by radiation (Table 6).
[0092] Experimental Example 6: Chinese herbal medicine composition reduces radiation-induced DNA damage in mouse intestinal cells
[0093] Implementation method: Mouse intestinal tissue immunofluorescence method. DNA damage detection kit (γ-H2AX immunofluorescence method) was used for detection, and the operation was carried out according to the instructions of the kit. After dewaxing and hydration, the tissue sections were fixed, blocked, incubated with primary antibodies, incubated with secondary antibodies, counterstained with cell nuclei, and sealed with anti-fluorescence quenching sealing liquid, and then image acquisition and analysis were performed.
[0094] Statistical analysis: Experimental data were expressed as mean ± standard deviation. The comparison among the groups was analyzed by t-test, and P<0.05 indicated significant difference.
[0095] Experimental results: Intestinal tissue will produce a large amount of lipid peroxides after being irradiated. These lipid peroxides stimulate cells, causing double-strand breaks in cell DNA and causing cell DNA damage. γ-H2AX protein is a marker of DNA damage in eukaryotic cells and is often used to assess the degree of DNA damage in tissues and cells. Compared with the normal control group, the protein expression level of γ-H2AX in the intestinal tissue of mice after radiation was significantly increased (P<0.01), indicating that obvious DNA damage occurred in the intestinal tissue cells of the model mice. Compared with the model group, the expression of γ-H2AX protein in the Chinese medicine composition groups with different doses decreased in a dose-dependent manner, indicating that the Chinese medicine composition can reduce the DNA damage of mouse intestinal cells caused by radiation (Table 6).
[0096] Table 6 Effects of Chinese medicine combination on proliferation, apoptosis and DNA damage of RII intestinal tissue cells
[0097]
[0098] ## P<0.01 compared with the normal group; ** P<0.01 compared with the model group
[0099] Test Example 7: Chinese herbal medicine composition enhances the antioxidant capacity of the intestine
[0100] Implementation method: Enzyme-linked immunosorbent assay (ELISA). Collect mouse serum after modeling. According to the instructions of SOD and MDA ELISA kits: dilute the standard sample in a concentration gradient; add the standard sample and cell supernatant to the antibody-coated wells, incubate at 37°C for 2 hours, and wash away the free components with washing solution; add 100 μL of detection antibody to the wells, 100 μL of HRP-labeled streptavidin, 100 μL of TMB colorimetric solution, and 100 μL of stop solution to stop the reaction. Measure the OD value of each well at a wavelength of 450 nm with an enzyme-labeled instrument, and calculate the content of SOD and MDA in mouse serum.
[0101] Statistical analysis: Experimental data were expressed as mean ± standard deviation. The comparison among the groups was analyzed by t-test, and P<0.05 indicated significant difference.
[0102] Experimental results: Oxidative stress is a key factor in the mechanism of intestinal ischemia-reperfusion injury. Compared with the normal control group, radiation can cause a significant decrease in the activity of the intestinal antioxidant enzyme SOD (P<0.01) and a large amount of lipid peroxide MDA (P<0.01). Compared with the model group, the Chinese medicine composition can reduce the MDA content of radiation-damaged intestinal tissue, increase the SOD content, and enhance the antioxidant capacity of the intestine (Table 7).
[0103] Table 7 Effect of Chinese herbal medicine combination on MDA and SOD secretion in RII intestinal tissue
[0104]
[0105] ## P<0.01 compared with the normal group; ** P<0.01, * P<0.05 compared with the model group
[0106] Test Example 8: Chinese herbal medicine composition inhibits intestinal inflammatory response caused by radiation damage
[0107] Implementation method: Same as Experimental Example 7. Operate according to the instructions of IL-1β, IL-6, IL-10 and TNF-α ELISA kits.
[0108] Statistical analysis: Experimental data were expressed as mean ± standard deviation. The comparison among the groups was analyzed by t-test, and P<0.05 indicated significant difference.
[0109] Experimental results: The intestine will have excessive inflammatory response after radiation damage. Compared with the normal control group, radiation can lead to increased expression levels of intestinal pro-inflammatory factors TNF-α, IL-1β, and IL-6 (P<0.01), and decreased expression levels of anti-inflammatory factor IL-10 (P<0.01). This shows that the Chinese medicine composition can inhibit the expression level of inflammatory factors to a certain extent and inhibit the intestinal inflammatory response caused by radiation damage (Table 8).
[0110] Table 8 Effect of Chinese medicine combination on secretion of inflammatory factors in RII intestinal tissue
[0111]
[0112] ## P<0.01 compared with the normal group; ** P<0.01, * P<0.05 compared with the model group
[0113] Based on the above description of the invention, those skilled in the art can fully apply the present invention, and all modifications based on the same principles or similar principles should be considered to be included in the scope of the present invention.
Claims
1. A Chinese medicine composition for treating radiation enteropathy, characterized in that: The invention is prepared from the following Chinese medicinal raw materials in parts by weight: 120-200 parts of kudzu root, 20-100 parts of scutellaria baicalensis, 20-100 parts of coptis root and 10-80 parts of roasted liquorice root.
2. The Chinese medicine composition according to claim 1, characterized in that The invention is prepared from the following Chinese medicinal raw materials in parts by weight: 140-180 parts of kudzu root, 40-80 parts of scutellaria baicalensis, 40-80 parts of coptis root and 30-60 parts of roasted liquorice root.
3. The Chinese medicine composition according to claim 1, characterized in that The invention is prepared from the following Chinese medicinal raw materials in parts by weight: 168 parts of kudzu root, 63 parts of scutellaria baicalensis, 63 parts of coptis root and 42 parts of roasted liquorice root.
4. Use of the Chinese medicine composition according to claims 1 to 3 in the preparation of medicines for treating radiation enteropathy.
5. The use according to claim 4, characterized in that: The radiation enteropathy is selected from the group consisting of acute / chronic enteropathy, intestinal fibrosis and enteritis caused by x-rays, gamma-rays, alpha-rays, beta-rays or neutron rays.
6. The use according to claim 4, characterized in that: The drug is used to maintain intestinal barrier function, alleviate intestinal obstruction, and improve intestinal motility deficiency; or The drug is used to promote the proliferation of intestinal mucosal epithelial cells, improve intestinal vascular permeability, and alleviate symptoms such as ulcers and intestinal bleeding; or The drug is used to reduce fibrotic lesions after intestinal epithelial cell damage and repair; or The drug is used to improve the antioxidant capacity of intestinal tissue cells and improve the aging and apoptosis lesions of intestinal tissue cells.
7. A medicine for treating radiation enteropathy, comprising the Chinese medicine composition of claims 1 to 3 and pharmaceutically acceptable excipients.
8. The drug according to claim 7, characterized in that The drug is administered orally or by enema, preferably orally; Preferably, the medicine is a decoction, powder, pill, granule, tablet, capsule, syrup or mixture, more preferably a capsule, granule or tablet.
9. A method for preparing the drug according to claim 7 or 8, comprising the following steps: The four Chinese medicinal materials are boiled in water, filtered, and the filtrates are combined and concentrated into extracts; Preferably, the amount of water added to the decoction of the Chinese medicinal material is 6 to 10 times its mass; the decoction time is 1 to 3 hours each time, and the decoction is performed 2 to 3 times; the concentration temperature is 60° C.; and the relative density of the concentrated extract is 1.10 to 1.20; Further preferably, the amount of water added to the decoction of the Chinese medicinal material is 8 times its mass, the decoction time is 2 hours, the decoction is performed twice, and the relative density of the concentrated extract is 1.
10.
10. The preparation method according to claim 9, characterized in that: The following steps are also included: Adding dextrin and lactose to the extract, wherein the mass ratio of the extract to dextrin and lactose is 1-3:1-6:0.5-2, making wet granules, drying and sieving the whole granules to obtain granules; or The extract is dried, crushed, mixed to obtain dry extract powder, and directly filled into capsules to obtain capsules; or The extract is dried, crushed, and mixed to obtain dry paste powder, dextrin is added, and 90% ethanol is used as a binder to prepare wet granules, which are granulated after drying, and magnesium stearate and / or low-substituted hydroxypropyl cellulose and / or polyethylene glycol and / or sodium carboxymethyl starch are added, and then tabletted to obtain tablets; wherein the mass ratio of the dry paste powder to dextrin, magnesium stearate or polyethylene glycol, low-substituted hydroxypropyl cellulose or sodium carboxymethyl starch is 3-5:3-5:0.1-0.3:0.5-1.
Citation Information
Patent Citations
Preparation process of integration-type novel formulation of Radix Puerariae, Rhizoma Coptidis and Scutellaria baicalensis decoction and production method thereof
CN102846753A
Cited By
Traditional Chinese medicine composition for treating radioactive injury and application thereof
CN120860138A
